The lack of involvement of the immune system's regulatory arm in the antitumor activity of FTS (Figure 3), together with the finding that Foxp3 in GL261 glioma cells was decreased after FTS treatment, suggested that the Foxp3-depleted GL261 glioma cells might behave like lymphocytes, and accordingly produce a pro-inflammatory microenvironment. The gene discussed is FOXP3; the disease is central nervous system cancer.